Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.11M | 24.43M | 37.20M | 30.56M | 29.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.11M | 24.43M | 37.20M | 30.56M | 29.73M |
| Cost of Revenue | 2.21M | 1.23M | 1.74M | 1.63M | 1.15M |
| Gross Profit | 26.90M | 23.20M | 35.45M | 28.94M | 28.58M |
| SG&A Expenses | 21.62M | 24.31M | 30.52M | 19.65M | 22.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.97M | 37.02M | 37.08M | 23.64M | 31.97M |
| Operating Income | -13.86M | -12.59M | 120.00K | 6.93M | -2.24M |
| Income Before Tax | -14.43M | -18.03M | -66.00K | 7.63M | -1.58M |
| Income Tax Expenses | -164.00K | 549.00K | 1.30M | 1.69M | 662.00K |
| Earnings from Continuing Operations | -14.27M | -18.58M | -1.37M | 5.94M | -2.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3.67M | 8.28M | -357.00K | -2.33M | 2.84M |
| Net Income | -10.61M | -10.30M | -1.72M | 3.61M | 598.00K |
| EBIT | -13.86M | -12.59M | 120.00K | 6.93M | -2.24M |
| EBITDA | -12.38M | -11.92M | 815.00K | 7.58M | -1.23M |
| EPS Basic | -0.12 | -0.14 | -0.02 | 0.04 | -0.02 |
| Normalized Basic EPS | -0.05 | 0.01 | -0.01 | 0.03 | 0.02 |
| EPS Diluted | -0.12 | -0.14 | -0.02 | 0.03 | -0.03 |
| Normalized Diluted EPS | -0.05 | 0.01 | -0.01 | 0.02 | 0.02 |
| Average Basic Shares Outstanding | 100.64M | 91.37M | 91.16M | 90.85M | 89.12M |
| Average Diluted Shares Outstanding | 100.64M | 91.37M | 91.16M | 103.97M | 89.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |